|
24.01.2025 17:00:08
|
EQS-Adhoc: Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million
|
EQS-Ad-hoc: Pentixapharm Holding AG / Key word(s): Preliminary Results Berlin, January 24, 2025 - According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the operating loss of EUR 7 million, the total also includes non-cash write-downs for intangible assets. They result from the termination of development projects at the subsidiary Myelo Therapeutics GmbH, which were previously mainly financed by contracts from various US government agencies. According to the opinion of the Management Board and Supervisory Board, the recent change in the U.S. administration has significantly worsened the conditions for amortization, as previous funding programs have been canceled or not extended. The annual report for 2024 with details of the development project will be published on April 15, 2025. For more information, please contact: Pentixapharm Holding AG End of Inside Information Information and Explanation of the Issuer to this announcement: About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
24-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2074627 |
| End of Announcement | EQS News Service |
|
|
2074627 24-Jan-2025 CET/CEST
Nachrichten zu Pentixapharm Holding AG Unitary
Analysen zu Pentixapharm Holding AG Unitary
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Pentixapharm Holding AG Unitary | 2.92 | -6.56% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
US-Börsen im Rückwärtsmodus -- SMI geht im Plus ins Wochenende -- DAX schliesst nach Rekordhoch über 21'500-Punkte-Marke etwas tiefer -- Hang Seng legt letztlich kräftig zuDer heimische Aktienmarkt zeigte sich am Freitag etwas höher, während der deutsche Leitindex nach neuen Rekorden ins Minus drehte. Die US-Börsen notierten schwächer. Die asiatischen Indizes zeigten sich zum Wochenausklang überwiegend freundlich.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |